AEON Biopharma, Inc. (AEON)
SEC filings, financial facts, source resources, and Goglides workspace context for AEON Biopharma, Inc..
OpenSearch
Find research, discussions, posts, companies, and topics.
Search uses Goglides API results from the projection-backed discovery index. Private, draft, hidden, unpublished, and admin-only content stays out of public results.
8Results7Tickers
Refine results
Recent Searches
Signed-in searches appear here after you use search.
Trending
XORTX Therapeutics Inc.: the filing proof gates that matter nowWilliams Companies: natural-gas infrastructure cash flow has to outlast capex and rate riskAurora Cannabis (ACB): the medical-cannabis turnaround trying to outrun dilutionAbbVie Inc. (ABBV) Coverage Bootstrap: Skyrizi and Rinvoq-led biopharma transition after HumiraAmbev (ABEV) Coverage Bootstrap: beer-led scale, Brazil execution, pricing discipline, and cash returnsAsbury Automotive Group (ABG) Coverage Bootstrap: dealership scale, service profit, F&I scrutiny, and leverage disciplineAble View Global (ABLV) Coverage Bootstrap: China beauty brand management, channel concentration, controlled voting, and listing riskABM Industries (ABM) Coverage Bootstrap: facility services scale, margin recovery, WGNSTAR integration, and labor execution
Top Tickers
Popular Tags
Tag facets appear after tag usage counts are rebuilt.
Results
Save searchLatest indexed results
Showing public results only.
Realty Income: the monthly dividend name still has a capital-cost test
Realty Income reported FY2025 revenue of $5.7 billion and Q1 2026 revenue of $1.5 billion. The thesis depends on lease durability, acquisition spreads, balance-sheet access, tenant concentration and cash conversion.
OpenEQIX: AI demand is exciting, but the data-center math has to beat the capital bill
Equinix reported FY2025 revenue of $9.2 billion, operating cash flow of $3.9 billion and Q1 2026 revenue of $2.4 billion. The thesis depends on interconnection demand, data-center utilization, power availability, debt capacity and capital efficiency.
OpenAHR: senior-housing NOI growth, with dilution math attached
American Healthcare REIT has visible senior-housing same-store NOI growth, positive GAAP earnings and raised 2026 normalized FFO guidance, but forward equity settlement, RIDEA operating exposure, Trilogy dependence and capital deployment decide the per-share c
OpenAHT: RevPAR is up, but the loan wall still runs the story
Ashford Hospitality Trust reported better Q1 comparable RevPAR and hotel EBITDA, but the Q1 2026 10-Q includes going-concern doubt, $1.9 billion of near-term non-recourse loan maturities, defaulted loans and suspended preferred dividends. AHT is a high-risk lo
OpenAHRT: the rebrand is really a balance-sheet reset
AH Realty Trust has turned the former Armada Hoffler platform into a retail and office REIT, with a $562 million multifamily sale agreement, high leased occupancy and a bigger buyback authorization. The proof gate is whether asset sales reduce leverage before
OpenAEON Biopharma: the BOTOX biosimilar bet running on a Q3 cash runway
AEON is trying to turn ABP-450 into a U.S. therapeutic BOTOX biosimilar, but the current setup combines FDA-pathway optionality with no commercial revenue, going-concern language, a short runway, listing pressure and heavy Daewoong concentration.
OpenAgree Realty: boring retail, aggressive buying, and a balance sheet built for rates
Agree Realty looks simple from far away: stores, rent, dividends. The useful question is sharper: can ADC keep buying long retail leases at yields that beat its capital cost?
Open